维布妥昔单抗联合风险适应性残留淋巴结放疗治疗儿童高危霍奇金淋巴瘤的优异结局
这项开放标签、单臂、多中心试验在≤18岁IIB、IIIB或IV期经典型霍奇金淋巴瘤患者中,用维布妥昔单抗替换OEPA/COPDac方案中的长春新碱,仅对早期反应评估未达完全缓解的淋巴结部位给予25.5 Gy残留淋巴结放疗。77例患者中27例(35%)在早期反应评估时达完全缓解并免于放疗;中位随访3.4年,3年无事件生存率97.4%(SE 2.3%),总生存率98.7%(SE 1.6%),仅4%患者发生3级神经病变。
要点
- 维布妥昔单抗替代长春新碱用于儿童高危经典型霍奇金淋巴瘤前线治疗,耐受性良好。
- 早期反应评估达完全缓解的27例(35%)患者免于放疗,显著减少放疗暴露。
- 中位随访3.4年,3年无事件生存率97.4%,总生存率98.7%,结局优异。
核心结论
- 将维布妥昔单抗整合入儿童高危经典型霍奇金淋巴瘤前线治疗高度可耐受,显著减少放疗暴露并取得优异结局。
研究设计与样本
- 开放标签、单臂、多中心试验,纳入年龄≤18岁、IIB/IIIB/IV期经典型霍奇金淋巴瘤患者77例。
- 按GPOH-HD2002治疗组3方案,用维布妥昔单抗替换OEPA/COPDac中每剂长春新碱,给予2周期AEPA和4周期CAPDac。
- 化疗结束后仅对2周期后早期反应评估未达完全缓解的淋巴结部位给予25.5 Gy残留淋巴结放疗。
主要发现
- 77例患者中27例(35%)在早期反应评估时达完全缓解并免于放疗。
- 中位随访3.4年,3年无事件生存率为97.4%(SE 2.3%),总生存率为98.7%(SE 1.6%)。
- 1例接受放疗的患者在治疗结束时出现疾病进展,经挽救治疗后无病生存超过6年;另发生1例意外死亡。
- 仅4%的患者发生3级神经病变。
关键数值与推荐
- 残留淋巴结放疗剂量为25.5 Gy,仅用于早期反应评估未达完全缓解的淋巴结部位。
- 主要目标为评估联合方案的安全性和疗效(早期反应评估时完全缓解)以及3年无事件生存率和总生存率。
临床怎么用
- 儿童高危经典型霍奇金淋巴瘤可考虑以维布妥昔单抗替换长春新碱,并根据早期反应评估结果选择性给予残留淋巴结放疗。
- 早期反应评估达完全缓解的患者可安全免于放疗,减少放疗相关远期毒性。
局限性
- 单臂设计,无随机对照,样本量77例,随访时间中位3.4年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL. METHODS: Open-label, single-arm, multicenter trial for patients (age ≤ 18 years) with stage IIB, IIIB, or IV classical HL was conducted. Brentuximab vedotin replaced each vincristine in the OEPA/COPDac (vincristine, etoposide, prednisone, and doxorubicin/cyclophosphamide, vincristine, prednisone, and dacarbazine) regimen according to GPOH-HD2002 treatment group 3 (TG3); two cycles of AEPA and four cycles of CAPDac. Residual node radiotherapy (25.5 Gy) was given at the end of all chemotherapy only to nodal sites that did not achieve a complete response (CR) at the early response assessment (ERA) after two cycles of therapy. Primary objectives were to evaluate the safety and efficacy (complete remission at ERA) of this combination and the 3-year event-free (EFS) and overall survival (OS). The trials are registered at ClinicalTrials.gov (identifier: NCT01920932). RESULTS: Of the 77 patients enrolled in the study, 27 (35%) achieved complete remission at ERA and were spared radiation. Patients who were irradiated received radiation to individual residual nodal tissue. At a median follow-up of 3.4 years, the 3-year EFS was 97.4% (SE 2.3%) and the OS was 98.7% (SE 1.6%). One irradiated patient experienced disease progression at the end of therapy and now remains disease free more than 6 years following salvage therapy, and one unexpected death occurred. Only 4% of patients experienced grade 3 neuropathy. CONCLUSION: The integration of brentuximab vedotin in the frontline treatment of pediatric high-risk HL is highly tolerable, facilitated significant reduction in radiation exposure, and yielded excellent outcomes.
引用
- Metzger ML, Link MP, Billett AL, et al. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. J Clin Oncol. 2021. PMID: 33826362. doi:10.1200/JCO.20.03286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。